Publications by authors named "B K Ballmer-Weber"
AAAAI-EAACI PRACTALL: Standardizing oral food challenges-2024 Update.
Pediatr Allergy Immunol
November 2024
Article Synopsis
Article Synopsis
- IgE-mediated food allergies are the most common type, causing quick and serious reactions that affect patients' and caregivers' lives.
- Omalizumab is a humanized monoclonal antibody that binds to IgE, reducing allergic reactions, and has been approved by the FDA for treating these food allergies.
- The GALEN ANACARE Consensus Statement supports omalizumab's use based on a systematic review and expert agreement, noting it is currently the only drug that can significantly reduce IgE-mediated food allergic reactions, although more evidence is needed for stronger guideline recommendations.
This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist.
View Article and Find Full Text PDFBackground: Celery root is known to cause severe allergic reactions in patients sensitized to mugwort pollen.
Objective: We studied clinically well-characterized patients with celery allergy by IgE testing with a comprehensive panel of celery allergens to disentangle the molecular basis of what is known as the celery-mugwort syndrome.
Methods: Patients with suspected food allergy to celery underwent a standardized interview.